Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Immuneering stock
Learn how to easily invest in Immuneering stock.
Immuneering is a biotechnology business based in the US. Immuneering shares (IMRX) are listed on the NASDAQ and all prices are listed in US Dollars. Immuneering employs 74 staff and has a trailing 12-month revenue of around $506,088.
How to buy Immuneering stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – IMRX. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
- Trade stocks and ETFs for $0 and no annual fee
- Minimum deposit of $10 required
- FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100
- Get free stock upon signup
- Earn 4% interest on uninvested cash with Robinhood Gold
- Get 1% match on contributions to a Robinhood IRA
Immuneering stock price (NASDAQ: IMRX)Use our graph to track the performance of IMRX stocks over time.
Immuneering shares at a glance
|Latest market close||$4.17|
|52-week range||$3.74 - $16.17|
|50-day moving average||$5.21|
|200-day moving average||$7.14|
|Wall St. target price||$17.40|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-2.12|
Buy Immuneering stocks from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Immuneering stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Immuneering price performance over time
|1 week (2023-01-26)||-5.44%|
|1 month (2022-12-30)||-14.02%|
|3 months (2022-11-02)||-68.24%|
|6 months (2022-08-02)||-30.27%|
|1 year (2022-02-02)||-57.23%|
|2 years (2021-01-29)||N/A|
|3 years (2020-01-29)||N/A|
|5 years (2018-01-29)||N/A|
|Gross profit TTM||$926,888|
|Return on assets TTM||-20.52%|
|Return on equity TTM||-34.3%|
|Market capitalisation||$116.4 million|
TTM: trailing 12 months
Immuneering share dividends
We're not expecting Immuneering to pay a dividend over the next 12 months.
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited. .
Immuneering in the news
Immuneering To Present at Guggenheim 2023 Oncology Conference
Frequently asked questionsWhat percentage of Immuneering is owned by insiders or institutions?
Currently 30.559% of Immuneering shares are held by insiders and 45.93% by institutions. How many people work for Immuneering?
Latest data suggests 74 work at Immuneering. When does the fiscal year end for Immuneering?
Immuneering's fiscal year ends in December. Where is Immuneering based?
Immuneering's address is: 245 Main Street, Cambridge, MA, United States, 02142 What is Immuneering's ISIN number?
Immuneering's international securities identification number is: US45254E1073
More guides on Finder
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
How to research stocks
Learn about stock analysis and how to use it to find the right company to buy.
Ask an Expert